The diagnostic value of a new formula combining age and prostate volume in prostate cancer
1Department of urology, General Hospital of Ningxia Medical University, 750004 Yinchuan, Ningxia, China
2School of Clinical Medicine, Ningxia Medical University, 750004 Yinchuan, Ningxia, China
Submitted: 15 April 2021 Accepted: 10 June 2021
Online publish date: 22 July 2021
† These authors contributed equally.
Background and objective: This study combined two clinical indicators (age and prostate volume (PV)) to generate age to PV (AVR) ratio, whose diagnostic value for prostate cancer (PCa) was examined based on prostate speciﬁc antigen (PSA) in the range of 4--20.0 ng/mL.
Methods: The medical records of patients who underwent transrectal ultrasound-guided biopsy of the prostate in our hospital from June 2015 to June 2019 were examined retrospectively. According to the pathological results of the biopsy, the patients were divided into the PCa and benign prostatic hyperplasia (BPH) groups. Receiver operating characteristic (ROC) curves for TPSA, PSAD, PV, (F/T)PSA, AVR, and PSA-AV were plotted with SPSS 26.0 and GraphPad Prism 5.0, and areas under the ROC curves (AUROCs) were determined and compared by Delong test. A log-linear model was used to compare AVR and other parameters with similar high sensitivities, for speciﬁcity.
Results: The AUROC for AVR was signiﬁcantly different from those of TPSA (p < 0.001), PV (p = 0.004),(F/T)PSA (p < 0.001), and PSA-AV (p = 0.006), and similar to that of PSAD (p = 0.064). With the same high sensitivity (90.0%), log-linear model analysis showed that the speciﬁcity of AVR was signiﬁcantly higher than those of TPSA and (F/T)PSA (p < 0.01), while there were no signiﬁcant differences among AVR and PSAD, PV and PSA-AV.
Conclusion: With PSA in the range of 4--20.0 ng/mL, AVR may be useful in sparing an invasive intervention for a number of patients.
Prostate cancer; Prostate-speciﬁc antigen density; PSA-AV score; Prostate-speciﬁc antigen
Xiaobo Yang,Jiahao Shan,Qiang Zhang,Zhongyu Yuan,Haoran Xu,Ziyang Liu,Xiaojie Zhou,Wenzhuo Ma,Hongbin Shi. The diagnostic value of a new formula combining age and prostate volume in prostate cancer. Journal of Men's Health. 2021.doi:10.31083/jomh.2021.080.
 Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, Etiology, Diagnosis and Treatment of Prostate Cancer. Asian Pacific Journal of Cancer Prevention. 2014; 15: 9575–9578.
 Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians. 2018; 68: 7–30.
 Li M, Zhang SW, Ma JH, Chen WQ, Na YQ. Comparative study on the incidence trend of prostate cancer in some cities and counties in China. Chinese Journal of Urology,2009(06):10-12.
 Han SJ, Zhang SW, Chen WQ, LI. CL. Analysis on the status and prevalence of prostate cancer in China. Clinical Oncology. 2013; 18: 330–334.
 Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen: a new potential marker for prostatic cancer. Prostate. 1981; 2: 89–96.
 Gui-zhong L, Libo M, Guanglin H, Jianwei W. The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. International Urology and Nephrology. 2011; 43: 295–301.
 Lee A, Lim J, Gao X, Liu L, Chia SJ. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore. Asia-Pacific Journal of Clinical Oncology. 2017; 13: e348–e355.
 Gupta M, McCauley J, Farkas A, Gudeloglu A, Neuberger MM, Ho Y, et al. Clinical practice guidelines on prostate cancer: a critical appraisal. Journal of Urology. 2015; 193: 1153–1158.
 Xie SW, Li HL, Du J, Xia JG, Guo YF, Xin M, et al. Influence of serum prostate-specific antigen (PSA) level, prostate volume, and PSA density on prostate cancer detection with contrast-enhanced sonography using contrast-tuned imaging technology. Journal of Ultrasound in Medicine. 2013; 32: 741–748.
 Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. Journal of the American Medical Association. 1993; 270: 860–864.
 Xie GS, Huang YH, Yan CY, Pu JX, Li G, Ouyang J, et al. Age-specific analysis of prostate-specific antigen and related parameters in 22055 middle-aged and elderly men. Chinese Journal of Urology. 2013; 34: 613–617.
 Chen R, Xie LP, Zhou LQ, Huang YR, Fu Q, He DL, et al. Investigation report on the status of prostate biopsy in member hospitals of China Prostate Cancer Alliance. Chinese Journal of Urology. 2015; 36: 342–345.
 Sighinolfi MC, Rocco B. Re: EAU Guidelines: Prostate Cancer 2019. European Urology. 2019; 76: 871.
 Page BR. The ‘student’’ of the student’s t‐test. Physics Teacher. 1995; 33: 490–496.
 Pacut A. How to use the Mann-Whitney test to detect a change in distribution for groups. Acta Neurobiologiae Experimentalis. 1987; 47: 19–26.
 Song HL, He J, Yu HT, Li L. Using the area under the ROC curve to evaluate and compare two related diagnostic tests. Journal of Second Military Medical University. 2006; 5.
 Qian J, Chen PY. Discussion on the Significance of Computational Observation Test Power in Hypothesis Test. Chinese Health Statistics. 2005; 3.
 Ma LM, Wang Jun. Application of log-linear model in clinical trial data analysis. Chinese Journal of Clinical Pharmacology. 2011; 3.
 Papsidero LD, Kuriyama M, Wang MC, Horoszewicz J, Leong SS, Valenzuela L, et al. Prostate antigen: a marker for human prostate epithelial cells. Journal of the National Cancer Institute. 1981; 66: 37–42.
 Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Human Pathology. 1993; 24: 220–226.
 Ford TF, Butcher DN, Masters JR, Parkinson MC. Immunocyto-chemical Localisation of Prostate-specific Antigen: Specificity and Application to Clinical Practice. British Journal of Urology. 1985; 57: 50–55.
 Rosenberg S, Stracher A, Burridge K. Isolation and characterization of a calcium-sensitive alpha-actinin-like protein from human platelet cytoskeletons. Journal of Biological Chemistry. 1981; 256: 12986–12991.
 Yamamoto S, Maruyama T, Kondoh N, Nojima M, Takiuchi H, Hirota S, et al. Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/mL. International Urology and Nephrology. 2008; 40: 85–89.
 Caliskan S. Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤4 ng/mL) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/mL). Journal of Cancer Re-search and Therapeutics. 2017; 13: 279–283.
 Huang Y, Li ZZ, Huang YL, Song HJ, Wang YJ. Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: a meta-analysis. Medicine. 2018; 97: e0249.
 Zhou LQ, Chen WM, Na YQ, Huang YY, Feng T HJ. Comparison of serum PSA level and free PSA ratio in patients with benign prostatic hyperplasia and prostate cancer %. Chinese Journal of Urology. 2002; 33–36.
 Bo CL, Ma TL. Sichuan province in the central and western regions apparent healthy elderly prostate specific antigen reference range. Mark Immune Analysis and Clinical. 2019; 26: 1710–1713.
 Ozden E, Turgut AT, Talas H, Yaman O, Gogus O. Effect of dimensions and volume of the prostate on cancer detection rate of 12 core prostate biopsy. International Urology and Nephrology. 2007; 39: 525–529.
 Tang P, Jin X, Uhlman M, Lin Y, Deng X, Wang B, et al. Prostate volume as an independent predictor of prostate cancer in men with PSA of 10-50 ng ml-1. Asian Journal of Andrology. 2013; 15: 409–412.
 Zheng XY, Xie LP, Wang YY, Ding W, Yang K, Shen HF, et al. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. Journal of Cancer Research and Clinical Oncology. 2008; 134: 1207–1210.
 Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate specific antigen density to predict clinically significant prostate cancer. Scientific Reports. 2020; 10: 20015.
 Nan LB, Yin XT, Gao JP. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution. Medical Science Monitor. 2019; 25: 8345–8351.
 JL. Q. Disease burden analysis of prostate cancer in Chinese men from 1990 to 2013. Chinese journal of epidemiology. 2016; 6.
 Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP. An examination of prostate cancer trends in Australia, England, Canada and USA: is the Australian death rate too high? World Journal of Urology. 2015; 33: 1677–1687.
 Patel S, Issa MM, El-Galley R. Evaluation of novel formula of PSA, age, prostate volume, and race in predicting positive prostate biopsy findings. Urology. 2013; 81: 602–606.
 Uçer O, Yücetas U, Çelen I, Toktas G, Müezzinoglu T. Assessment of PSA-Age volume score in predicting positive prostate biopsy findings in Turkey. International Brazilian Journal of Urology. 2015; 41: 864–868.
 Wu YS, Wu XB, Zhang N, Jiang GL, Yu Y, Tong SJ, et al. Evaluation of PSA-age volume score in predicting prostate cancer in Chinese population. Asian Journal of Andrology. 2018; 20: 324–329.
 Gjengstø P, Paus E, Halvorsen OJ, Eide J, Akslen LA, Wentzel-Larsen T, et al. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. Journal of Urology. 2005; 173: 425–428.
Science Citation Index Expanded Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Social Sciences Citation Index Social Sciences Citation Index contains over 3,400 journals across 58 social sciences disciplines, as well as selected items from 3,500 of the world’s leading scientific and technical journals. More than 9.37 million records and 122 million cited references date back from 1900 to present.
Current Contents - Social & Behavioral Sciences Current Contents - Social & Behavioral Sciences provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in the social and behavioral sciences.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
SCOPUS Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
DOAJ DOAJ is a community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals.
CrossRef Crossref makes research outputs easy to find, cite, link, assess, and reuse. Crossref committed to open scholarly infrastructure and collaboration, this is now announcing a very deliberate path.
Portico Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections. Our unique, trusted process ensures that the content we preserve will remain accessible and usable for researchers, scholars, and students in the future.